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Abstract
Gitelman syndrome (GS), also referred to as familial hypokalemia-hypomagnesemia, is 
characterized by hypokalemic metabolic alkalosis in combination with significant hypomagnesemia 
and low urinary calcium excretion. The prevalence is estimated at approximately 1:40,000 and 
accordingly, the prevalence of heterozygotes is approximately 1% in Caucasian populations, making 
it one of the most frequent inherited renal tubular disorders. In the majority of cases, symptoms 
do not appear before the age of six years and the disease is usually diagnosed during adolescence 
or adulthood. Transient periods of muscle weakness and tetany, sometimes accompanied by 
abdominal pain, vomiting and fever are often seen in GS patients. Paresthesias, especially in the face, 
frequently occur. Remarkably, some patients are completely asymptomatic except for the 
appearance at adult age of chondrocalcinosis that causes swelling, local heat, and tenderness over 
the affected joints. Blood pressure is lower than that in the general population. Sudden cardiac 
arrest has been reported occasionally. In general, growth is normal but can be delayed in those GS 
patients with severe hypokalemia and hypomagnesemia.
GS is transmitted as an autosomal recessive trait. Mutations in the solute carrier familyl2, member 
3 gene, SLC12A3, which encodes the thiazide-sensitive NaCl cotransporter (NCC), are found in the 
majority of GS patients. A t present, more than 140 different NCC mutations throughout the whole 
protein have been identified. In a small minority of GS patients, mutations in the CLCNKB gene, 
encoding the chloride channel ClC-Kb have been identified.
Diagnosis is based on the clinical symptoms and biochemical abnormalities (hypokalemia, metabolic 
alkalosis, hypomagnesemia and hypocalciuria). Bartter syndrome (especially type III) is the most 
important genetic disorder to consider in the differential diagnosis of GS. Genetic counseling is 
important. Antenatal diagnosis for GS is technically feasible but not advised because of the good 
prognosis in the majority of patients.
Most asymptomatic patients with GS remain untreated and undergo ambulatory monitoring, once 
a year, generally by nephrologists. Lifelong supplementation of magnesium (magnesium-oxide and 
magnesium-sulfate) is recommended. Cardiac work-up should be offered to screen for risk factors 
of cardiac arrhythmias. All GS patients are encouraged to maintain a high-sodium and high 
potassium diet. In general, the long-term prognosis of GS is excellent.
Page 1 of 6
(page number not for citation purposes)
Orphanet Journal of Rare Diseases 2008, 3:22 http://www.ojrd.eom/content/3/1/22
Disease nam e and synonyms
Gitelman syndrome
Gitelman's syndrome
Familial hypokalemia-hypomagnesemia
Definition and epidemiology
Gitelman syndrome (GS) (OMIM 263800), also referred 
to as familial hypokalemia-hypomagnesemia, is an auto­
somal recessive salt-losing renal tubulopathy that is char­
acterized by hypomagnesemia, hypocalciuria and 
secondary aldosteronism, which is responsible for 
hypokalemia and metabolic alkalosis [1]. The prevalence 
is estimated at ~25 per million and accordingly, the prev­
alence of heterozygotes is approximately 1% in Caucasian 
populations, making it one of the most frequent inherited 
renal tubular disorders.
Clinical description
GS patients usually present above six years of age and in 
many cases the diagnosis is only made at adult age. Most 
patients suffer from tetany, especially during periods of 
fever or when extra magnesium is lost due to vomiting or 
diarrhea. Paresthesias, especially in the face, frequently 
occur. Some patients experience severe fatigue interfering 
with daily activities, while others never complain of tired­
ness. The severity of fatigue in GS is no t completely related 
to the degree of hypokalemia. In contrast to Bartter syn­
drome (a genetically distinct and clinically more severe 
tubular transport disorder, which shares the hypokalemic 
metabolic alkalosis with GS) polyuria is usually absent or 
only mild. In general, growth is normal in  GS patients, 
however, it can be delayed in  patients with severe hypoka­
lemia and hypomagnesemia [2].
Some adult GS patients suffer from chondrocalcinosis, 
which is assumed to result from chronic hypomag­
nesemia. It causes swelling, local heat, and tenderness 
over the affected joints. In earlier clinical reports addi­
tional symptoms, such as ataxia, vertigo, and blurred 
vision have been reported.
Cruz and colleagues have challenged the generally shared 
idea that GS is a mild disorder [3]. They evaluated the 
symptoms and quality of life (QOL) in 50 adult patients 
with molecularly proven GS and compared this cohort of 
patients with 25 age- and sex-matched controls. They 
found that GS patients had significantly more complaints 
than controls, mainly salt craving, musculoskeletal symp­
toms such as tetany and cramps, muscle weakness and 
aches, and constitutional symptoms such as fatigue, gen­
eralized weakness and dizziness, and nocturia and poly­
dipsia. In addition, measures of QOL were significantly 
lower in  GS patients compared to controls.
Potassium and magnesium depletion prolong the dura­
tion of the action potential of cardiomyocytes and conse­
quently increase the risk for development of ventricular 
arrhythmia. Electrocardiograms of patients with Gitelman 
syndrome have shown that in about 50% of cases the QT 
interval is indeed slightly to moderately prolonged but, 
fortunately, is not associated with clinically relevant car­
diac arrhythmias in the far majority of cases [4]. Sudden 
cardiac arrest reported in few patients with GS [2,5], war­
rants systematic cardiac screening for identifying other 
possible triggering mechanisms or underlying conditions. 
Blood pressure in  GS patients is lower than in  the general 
population, indicating that even the modest salt wasting 
of this disease reduces blood pressure. The results from a 
recent study in  35 GS-carriers (with one m utant gene 
allele) suggest that GS carriers also have lower blood pres­
sure and may be protected from hypertension [6]. 
Another study in  a large cohort also demonstrated 
reduced blood pressure in subjects having SLC12A3 m uta­
tions on one allele [7]. These results are distinct from a 
previous study in  an Amish kindred, in  which no reduc­
tion of blood pressure was demonstrated in  adult 
patients, despite increased Na+ excretion [8]. Thus, further 
studies are required to investigate whether the incidence 
of cardio-vascular events differs between GS patients or 
carries compared to control population.
Etiopathogenesis
In the great majority of cases GS is caused by mutations in 
the solute carrier family 12, member 3, SLC12A3 gene, 
which encodes the renal thiazide-sensitive sodium-chlo­
ride co-transporter NCC that is specifically expressed in 
the apical membrane of cells in the first part of the distal 
convoluted tubule (DCT) (reviewed in [9]). NaCl cotrans­
porter (NCC) is a polypeptide of 1021 amino acids and 
the 2D-structure is predicted to contain 12 transmem­
brane domains and long intracellular amino- and carbox- 
ytermini. At present, more than 140 different, putative 
loss-of-function mutations in the SLC12A3 gene have 
been identified in  GS patients. These mutations include 
missense-, nonsense-, frame-shift-, and splice-site m uta­
tions and are distributed throughout the whole protein.
In general, there is extreme inter- and intrafamiliar pheno­
type variability in GS, the latter emphasizing the lack of a 
correlation between the severity of symptoms in  GS and 
the type of m utation in the SLC12A3 gene [10]. Recently, 
however, Riviera-Munoz et al. described a small subgroup 
of patients with a remarkable severe phenotype, including 
an early onset, severe neuromuscular manifestations, 
growth retardation and ventricular arrhythmias [2]. The 
majority of these patients were male and carried at least 
one allele of a splice defect, resulting in a truncating tran­
script, or a non-functional intracellularly retained m uta­
tion (see below). They suggested from these data that the
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nature/position of the SLC12A3 m utation combined with 
male gender may be a determinant factor in  the severity of 
GS. Studies in  lager cohorts are necessary to confirm this 
assumption.
By functional expression studies and results of immuno- 
cytochemistry in Xenopus leavis oocytes, it was shown that 
most disease-causing NCC mutants are impaired in  their 
routing to the plasma membrane. Thus, the majority of 
mutations belong to the so-called type 2 mutations 
which, in contrast to type 1 mutations that impair protein 
synthesis, lead to fully synthesized proteins. These type 2 
m utant proteins, however, do not traffic appropriately to 
the plasma membrane, primarily due to protein misfold- 
ing and retention in  the endoplasmic reticulum, followed 
by rapid proteoasomal degradation. De Jong and co­
workers have shown that NCC misfolding resulting in 
defective trafficking in  GS is not uniformly complete [11]. 
Some m utant NCC proteins are only partially retarded in 
their trafficking; they do reach the plasma membrane, 
albeit to a limited extent, and are partially active. Subse­
quently, it was demonstrated that the intrinsic activity of 
these partially retarded mutants is unaffected by the m uta­
tion [12,13]. This finding opens the possibility of phar­
macological chaperones, facilitating the routing of 
misfolded, trafficking-defective, but otherwise functional 
NCCs to the apical membrane, for therapeutic use. 
Indeed, in  an additional study, de Jong et al. found prove 
that the transcriptional regulator 4-phenylbutyrate may 
be a promising candidate for rescuing partially retarded, 
but otherwise functional m utant NCCs [14]. Recently, 
another class of mutations in GS was identified by Riveira- 
Munoz et al. [15]. This newly identified class includes 
mutants which are partly retained in  the cell, but in  con­
trast to the mutants mentioned above, these mutants do 
not show any activity when they reach the cell surface.
A minority of patients with the Gitelman phenotype has 
been shown to have mutations in the CLCNKB gene, 
encoding the renal chloride channel ClC-Kb, located in 
basolateral membrane of cells of the thick ascending limb 
of Henle's loop (TAL) and the distal tubules. Mutations in 
the CLCNKB gene were previously found to be the cause 
of classic Bartter syndrome. It is now evident that the clin­
ical phenotype in patients with CLCNKB mutations can 
be highly variable, from an antenatal onset of Bartter syn­
drome on one side of the spectrum, to a phenotype closely 
resembling Gitelman syndrome at the other side (review 
in [9]). Therefore, there is an indication to screen the CLC- 
NKB gene in  patients with the Gitelman phenotype who 
do not have mutations in the SLC12A3 gene.
Both loss-of-function mutations in  NCC and mutations in 
CLC-Kb lead to disruption of NaCl reabsorption in  the 
DCT (figure 1). When less NaCl is reabsorped, more
sodium will arrive in  the collecting duct resulting in  mild 
volume contraction. The reduced vascular volume acti­
vates the renin-angiotensin-aldosterone system, increas­
ing renin activity and aldosterone levels. The elevated 
aldosterone levels give rise to increased electrogenic 
sodium reabsorption in  the cortical collecting duct via the 
epithelial sodium channel (ENaC), defending salt hom e­
ostasis at the expense of increased secretion of potassium 
and hydrogen ions, thus resulting in  hypokalemia and 
metabolic alkalosis. It has been shown that passive Ca2+ 
reabsorption in  the proximal tubule and reduced abun­
dance of the epithelial Mg2+ channel TRPM6, located in  
the DCT explains thiazide-induced hypocalciuria and 
hypomagnesemia, respectively [16]. Since thiazides are 
known to inhibit NCC, and in  view of the phenotypic 
resemblance between GS and chronic thiazide-treatment, 
it is very likely that similar mechanisms are involved in 
the pathogenesis of respectively hypocalciuria and 
hypomagnesemia seen in  GS.
Diagnosis, diagnostic m ethods and differential 
diagnosis
The diagnosis of Gitelman syndrome is based on the clin­
ical symptoms and biochemical abnormalities. The most 
typical biochemical abnormalities in  GS are hypokalemia, 
metabolic alkalosis, hypomagnesemia and hypocalciuria. 
Serum potassium concentration is comparably low (2.7 ± 
0.4 mmol/L) to Bartter syndrome. Serum magnesium con­
centration is low (less than 0.65 mmol/l). In a few GS 
patients magnesium concentration is easily maintained in 
the normal range early on, which may lead to a false diag­
nosis of Bartter syndrome, and only drops below normal 
with time (personal observation). Urinary calcium con­
centration is usually less than 0.2 m m ol/m m ol creatinine 
and rarely exceeds 0.5 mg/kg/day. Hypomagnesemia and 
hypocalciuria have always been considered obligate fea­
tures for GS. This assumption has recently been disputed 
by Lin et al. [10]. They reported two families with molec­
ularly proven GS, in  which male patients had severe 
hypokalemia, and were symptomatic with episodes of 
paralysis, impaired urinary concentration ability, bu t with 
normal serum magnesium and urinary calcium excretion. 
Remarkably, female GS patients within these families, car­
rying the same causative mutations as the male patients, 
were asymptomatic, had less severe hypokalemia, intact 
urine concentration ability, but did have hypomag­
nesemia and hypocalciuria [10]. Although this was a 
small study, the authors concluded that gender may affect 
phenotypic expression in  GS and that hypomagnesemia 
and hypocalciuria may not be invariant features of the dis­
order.
Prostaglandin excretion is normal and plasma renin activ­
ity and plasma aldosterone concentration are only slightly 
elevated compared to Bartter syndrome. Renal functional
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Figure!
A  m odel o f tra n s p o rt m echanisms in th e  DCT. Sodium-chloride (NaCl) enters the cell via the apical thiazide-sensitive 
NCC and leaves the cell through the basolateral Cl- channel (ClC-Kb), and the Na+/K+-ATPase. Indicated also are the recently 
identified magnesium channel TRPM6 in the apical membrane, and a putative Na/Mg exchanger in the basolateral membrane.
studies have demonstrated normal or slightly decreased 
urinary concentrating mechanism, bu t clearly reduced dis­
tal fractional chloride reabsorption during hypotonic 
saline infusion. GS patients have a blunted natriuretic 
response to hydrochlorothiazide administration but a 
prom pt natriuresis after administration of furosemide,
indicating that the defect in GS is located at the level of the 
distal tubule. DNA m utation analysis of the gene respon­
sible for GS may confirm the diagnosis.
Bartter syndrome is the most im portant genetic disorder 
to consider in the differential diagnosis of GS. Especially
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type III Bartter syndrome, which is caused by mutations in 
the CLCNKB gene, is clinically and biochemically overlap­
ping with Gitelman syndrome. The other types of Bartter 
syndrome usually have an earlier onset and a more severe 
phenotype.
Primary forms of renal hypomagnesemia can be distin­
guished from GS by the absence of hypokalemia. Impor­
tant acquired conditions which should be differentiated 
from GS are diuretic and laxative abuse and chronic vom­
iting. The two latter conditions can be confirmed by meas­
uring of low urinary excretion of Cl-.
Genetic counseling
Genetic counseling is important. Since GS is an autosomal 
recessive trait, the recurrence risk for parents with an 
affected child is 25%. If the parents already have other 
children, who are not obviously affected, it is not abso­
lutely sure that they do not have GS because clinical symp­
toms can appear later in  life. If the parents are eager to 
know the status of the other child(ren) and in case the 
molecular defect in  their affected child has been eluci­
dated, DNA-analysis in the other child(ren) may be per­
formed. Adult patients with GS have a low risk of having 
children with GS (~1 in 400) unless the patient and his/ 
her partner are consanguineous. Although technically fea­
sible, antenatal diagnosis for GS is not advised and as yet 
has never been asked for because of the good prognosis in 
the majority of patients.
M anagem ent including trea tm en t
Most asymptomatic patients with GS remain untreated 
and undergo ambulatory monitoring (generally by neph­
rologists) with low frequency (1-2  times per year). At 
each visit complaints related to hypokalemia (fatigue, 
muscle weakness, constipation, cardiac arrhythmias) and 
hypomagnesemia (tetany, cramps, paresthesias, joint and 
muscle pain) as well as serum levels of K+, bicarbonate 
and Mg2+ should be evaluated. In view of the assumption 
that chondrocalcinosis is due to magnesium deficiency 
(magnesium is a co-factor of various pyrophospatases, 
including alkaline phosphatase), there is a clear argument 
for lifelong supplementation of magnesium. Normaliza­
tion of serum magnesium is difficult to achieve since high 
doses of magnesium cause diarrhea. The bio-availability 
of magnesium preparations is different. Magnesium-oxide 
and magnesium-sulfate have a significantly lower bio­
availability compared to magnesium-chloride, magne- 
sium-lactate and magnesium-aspartate. We recommend 
the administration of magnesium-chloride orally to com­
pensate for renal Mg2+ and Cl- losses. Initial daily dose is 3 
mmol Mg/m2/24 hrs or 4-5  mg/kg/24 hrs. This dose 
should be divided in 3 -4  administrations to avoid 
diarrhea and has to be adjusted according to serum mag­
nesium levels. The dose usually has to be increased during
periods of undercurrent infections especially those 
accompanied by vomiting and diarrhea. In case of acute 
tetany, 20% MgCl2 should be administered intravenously 
(0.1 mmol Mg/kg per dose) and can be repeated every 6 
hours.
Complaints related to chondrocalcinosis (mainly pseudo­
gout attacks) are caused by the deposition of calcium 
pyrophosphate dehydrate crystals in  synovium and the 
synovial fluid and can be reduced by Mg2+ supplementa­
tion [17]. The symptoms can be controlled by non-steroi­
dal anti-inflammatory drugs (NSAID) and joint surgery is 
generally no t required.
If symptomatic hypokalemia is not corrected by MgCl2 
administration, it can be treated by drugs that antagonize 
the activity of aldosterone or block the sodium channel 
ENaC in the collecting duct. We prefer the combination of 
amiloride (5-10 mg/1.73 m2/day) with KCl (1-3 mmol/ 
kg/day divided in 3 -4  doses). Amiloride should be started 
with caution in  order to avoid hypotension.
Growth and puberty delay in  some patients with severe 
GS can be corrected by adequate Mg and K supplementa­
tion and a growth-promoting effect of indomethacin was 
also reported in GS patients [18]. Cardiac work-up is rec­
ommended to screen for risk factors of cardiac arrhyth­
mias. All patients with GS are encouraged to maintain a 
high-sodium and high potassium diet.
Prognosis
In general, the long-term prognosis of Gitelman syn­
drome is excellent. However, the severity of fatigue may 
seriously ham per some patients in  their daily activities. 
Progression to renal insufficiency is extremely rare in  GS. 
As yet, only one patient who developed chronic renal 
insufficiency and subsequent progression to end-stage 
renal disease has been reported [19].
Abbreviations
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